BioCentury | Apr 14, 2020
Finance
Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders
...CVN424, from Takeda after the Japanese pharma obtained its rights through its 2012 acquisition of Envoy Therapeutics Inc....